Outcome after surgical management of canine insulinoma in 49 cases.
insulinoma
metastasis
surgical oncology
Journal
Veterinary and comparative oncology
ISSN: 1476-5829
Titre abrégé: Vet Comp Oncol
Pays: England
ID NLM: 101185242
Informations de publication
Date de publication:
Sep 2021
Sep 2021
Historique:
revised:
15
06
2020
received:
02
03
2020
accepted:
15
06
2020
pubmed:
20
6
2020
medline:
27
1
2022
entrez:
20
6
2020
Statut:
ppublish
Résumé
Canine insulinoma has historically been associated with a poor prognosis; however, prolonged survival times have recently been reported. Prognostic indicators that are available preoperatively are of limited predictive accuracy, and consensus on post-operative treatment recommendations is lacking. The objectives of this study were to describe outcomes in dogs with insulinoma treated surgically, and to assess whether selected potential risk factors are strongly associated with outcomes after surgery. Medical records of two institutions were searched for dogs with insulinoma that were treated surgically. Forty-nine dogs were included. Thirty-nine dogs (80%) had immediate resolution of hypoglycaemia and 10 (20%) remained persistently hypoglycaemic postoperatively. The median survival time (MST) for all dogs was 561 days. The MST for dogs that had resolution of hypoglycaemia was 746 days. The median of the overall euglycaemic time (times from surgery to first detection of hypoglycaemia at any time point after surgery) for all dogs was 424 days. Forty-four percent of those that had resolution of hypoglycaemia experienced recurrence of hypoglycaemia by 2 years postoperatively. Pathological stage was a predictor of persistent post-operative hypoglycaemia which, in turn, was a predictor of survival time. These results show that dogs with insulinoma can have prolonged survival, and that pathological stage is a predictor of outcome.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
428-441Informations de copyright
© 2020 John Wiley & Sons Ltd.
Références
Goutal CM, Brugmann BL, Ryan KA. Insulinoma in dogs: a review. J Am Anim Hosp Assoc. 2012;48(3):151-163.
Tobin RL, Nelson RW, Lucroy MD, Wooldridge JD, Feldman EC. Outcome of surgical versus medical treatment of dogs with beta cell neoplasia: 39 cases (1990-1997). J Am Vet Med Assoc. 1999;215(2):226-230.
Polton GA, White RN, Brearley MJ, Eastwood JM. Improved survival in a retrospective cohort of 28 dogs with insulinoma. J Small Anim Pract. 2007;48(3):151-156.
Nelson RW. Beta-Cell Neoplasia: insulinoma. In: Feldman EC, Nelson RW, Reusch CE, Scott-Moncriefff JCR, eds. Canine and Feline Endocrinology. 4th ed. St. Louis MO: Elsevier; 2015:348-375.
Northrup NC, Rassnick KM, Gieger TL, Kosarek CE, McFadden CW, Rosenberg MP. Prospective evaluation of biweekly streptozotocin in 19 dogs with insulinoma. J Vet Intern Med. 2013;27(3):483-490.
Caywood DD, Klausner JS, O'Leary TP, et al. Pancreatic insulin-secreting neoplasms: clinical, diagnostic, and prognostic features in 73 dogs. J Am Anim Hosp Assoc. 1988;24(5):577-584.
Hixon LP, Grimes JA, Wallace ML, Schmiedt CW. Risk factors for gastrointestinal upset and evaluation of outcome following surgical resection of canine pancreatic β-cell tumors. Can Vet J. 2019;60(12):1312-1318.
Del Busto I, German AJ, Treggiari E, et al. Incidence of postoperative complications and outcome of 48 dogs undergoing surgical management of insulinoma. J Vet Intern Med. 2020;34(3):1135-1143.
Buishand FO, Visser J, Kik M, et al. Evaluation of prognostic indicators using validated canine insulinoma tissue microarrays. Vet J. 2014;201(1):57-63.
Buishand FO, Kik M, Kirpensteijn J. Evaluation of clinico-pathological criteria and the Ki67 index as prognostic indicators in canine insulinoma. Vet J. 2010;185(1):62-67.
Fukushima K, Fujiwara R, Yamamoto K, et al. Characterization of triple-phase computed tomography in dogs with pancreatic insulinoma. J Vet Med Sci. 2015;77(12):1549-1553.
Lamb CR, Simpson KW, Boswood A, Matthewman LA. Ultrasonography of pancreatic neoplasia in the dog: a retrospective review of 16 cases. Vet Rec. 1995;137(3):65-68.
Mai W, CÁCeres AV. Dual-phase computed tomographic angiography in three dogs with pancreatic insulinoma. Vet Radiol Ultrasound. 2008;49(2):141-148.
Kass RE, Raftery AE. Bayes factors. J Am Stat Assoc. 1995;90(430):773-795.
Goodman SN. Toward evidence-based medical statistics. 2: the Bayes factor. Ann Intern Med. 1999;130(12):1005-1013.
Goodman SN. Of P-values and Bayes: a modest proposal. Epidemiol. 2001;12:295-297.
Trifonidou MA, Kirpensteijn J, Robben JH. A retrospective evaluation of 51 dogs with insulinoma. Vet Q. 1998;20(suppl 1):S114-S115.
Nakamura K, Lim S-Y, Ochiai K, et al. Contrast-enhanced ultrasonographic findings in three dogs with pancreatic insulinoma. Vet Radiol Ultrasound. 2015;56(1):55-62.
Robben JH, Pollak YW, Kirpensteijn J, et al. Comparison of ultrasonography, computed tomography, and single-photon emission computed tomography for the detection and localization of canine insulinoma. J Vet Intern Med. 2005;19(1):15-22.
Buishand FO, Vilaplana Grosso FR, Kirpensteijn J, van Nimwegen SA. Utility of contrast-enhanced computed tomography in the evaluation of canine insulinoma location. Vet Q. 2018;38(1):53-62.
Dunn JK, Heath MF, Herrtage ME, Jackson KF, Walker MJ. Diagnosis of insulinoma in the dog: a study of 11 cases. J Small Anim Pract. 1992;33(11):514-520.
Flesner BK, Fletcher JM, Smithee T, Boudreaux B. Long-term survival and glycemic control with toceranib phosphate and prednisone for a metastatic canine insulinoma. J Am Anim Hosp Assoc. 2018;55(1):e551-e505.
Wouters EG, Buishand FO, Kik M, Kirpensteijn J. Use of a bipolar vessel-sealing device in resection of canine insulinoma. J Small Anim Pract. 2011;52(3):139-145.
Pratschke KM, Ryan J, McAlinden A, McLauchlan G. Pancreatic surgical biopsy in 24 dogs and 19 cats: postoperative complications and clinical relevance of histological findings. J Small Anim Pract. 2015;56(1):60-66.